-
| Sector | Healthcare |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US43157M1027 |
| Industry | Biotechnology |
| Market Cap | 96M |
|---|---|
| PE Ratio | None |
| Target Price | 2 |
| Beta | 0.78 |
| Dividend Yield | None |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda for the commercialization of any pharmaceutical products with HIL-214 compounds. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HLVX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025